Drug Target Review

NOVEMBER 1, 2023

2,8-10 However, the number of compounds with satisfying pharmacokinetic parameters (PKD) are limited, with most unable to cross the blood-brain barrier or go sufficiently deep into a malignant tumour. Pleotropic Roles of Autotaxin in the Nervous System Present Opportunities for the Development of Novel Therapeutics for Neurological Diseases.

Clinical Trials 134

Clinical Trials Trials Small Molecule Disease 134

The Pharma Data

NOVEMBER 17, 2020

The study demonstrated favorable proof-of-concept for LYT-100’s tolerability and pharmacokinetic (PK) profile, which will also enable twice-a-day (BID) dosing of LYT-100 in future studies. Photo: Business Wire). Each forward-looking statement speaks only as at the date of this press release.

Pharmacokinetics 52

Pharmacokinetics Treatment Trials Production 52

The Pharma Data

APRIL 11, 2023

The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Data from all three areas of scientific focus will be showcased during this year’s meeting.

Research 40

Research Clinical Trials Small Molecule Trials 40

New Drug Approvals

JUNE 25, 2025

2011, 2 , 828-839 DOI: 10.1039/C1MD00116G [link] [link] Glucokinase is a key regulator of glucose homeostasis and small molecule activators of this enzyme represent a promising opportunity for the treatment of Type 2 diabetes. clinical candidate currently in Phase 2 development. Glucokinase activators 1 and 2. PATENT Pfizer Inc.

Small Molecule 62

Small Molecule Treatment Regulations Drugs 62

The Pharma Data

NOVEMBER 11, 2020

As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. “As About SLV213.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

Practical Cheminformatics

JANUARY 8, 2024

In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. A paper by Bran and coworkers from EFPL and the University of Rochester presented ChemCrow, a system for integrating Chemistry capabilities into LLMs. Drug discovery is inherently an MPO problem.

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

The Premier Consulting Blog

JULY 31, 2024

Regulatory Pathway 505(b)(2) versus 505(b)(1) In the US, novel new small molecule drug products, including some peptides, are regulated, and approved by the FDA under the Federal Food, Drug, and Cosmetic Act (the “Federal FD&C Act”) under two key regulatory pathways: Section 505(b)(1) and Section 505(b)(2) NDAs.

Clinical Pharmacology 52

Clinical Pharmacology Drug Development Pharmacokinetics Drugs 52

The Premier Consulting Blog

AUGUST 8, 2024

For example, pharmacokinetic (PK) data from a comparative BA study and PK modeling approaches (e.g., Typically, new drug development under the 505(b)(2) pathway requires less capital and time and has a higher success rate versus the 505(b)(1) pathway, where the Sponsor develops safety and effectiveness information from scratch.

Drugs 52

Drugs Pharmacokinetics FDA Production 52

The Pharma Data

JANUARY 19, 2021

This small molecule therapy is presently in Phase 1 clinical trial for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. CLARKSVILLE, Md., 20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , About Neuronascent, Inc.

Disease 40

Disease Small Molecule Clinical Trials Therapies 40

Metabolite Tales Blog

DECEMBER 13, 2023

Conjugation of small molecule drugs to glucuronic acid is catalysed by several UGTs to frequently form N – and O -glucuronides. As in this example, most N -glucuronides of small molecule drugs are innocuous and possess no pharmacological activity. J Pharm Biomed Anal. Sundararaghavan VL, Sindhwani P, Hinds TD Jr.

Small Molecule 59

Small Molecule Metabolic Stability Treatment Drugs 59

Drug Target Review

JULY 12, 2023

Once a new drug target is identified, a proprietary deep learning artificial intelligence (AI) platform we call Fluency can rapidly identify small molecules that selectively bind to a target of interest. We are pleased that to date our lead product candidate has aligned DCI profiles as expected.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

New Drug Approvals

APRIL 18, 2025

A representative Coupling-Step of 2-cyclopropylacetic acid ( Compound 1A) with N,O-dimethylhydroxylamine or a salt thereof in the presence of a coupling-step reagent (e.g., 1,1-carbonyldiimidazole), a coupling-step base (e.g., triethylamine), and a coupling-step solvent (e.g., Br), in the presence of an alkylating-step solvent (e.g., PMC 10583973.

FDA 62

FDA FDA Approval Drugs Trials 62

The Pharma Data

JANUARY 10, 2021

Independently optimized receptor bias and potency as well as pharmacokinetics to create a potentially best-in-class IL-2 product. Presentation at J.P. Morgan presentation will be available on the Events & Presentations section of the investor relations webpage at [link]. ?. . .

Clinical Trials 40

Clinical Trials Clinical Development Small Molecule Trials 40

The Pharma Data

AUGUST 29, 2020

Basel, August 29, 2020 — Novartis today announced new Phase II data for LNP023, an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the virtually held 2020 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting. Blood 2019;134(Suppl 1):3517. 3. Schubart A, et al.

Treatment 52

Treatment Disease Small Molecule Production 52

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. Several small molecule GLP-1R agonists, such as oral orforglipron, are in late-stage clinical development.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

The Pharma Data

NOVEMBER 4, 2020

New CTP-543 Data Presented in Late-Breaking News Session at EADV 2020. Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This has spawned a movement focused on optimizing dose selection in oncology drug development.

Science 40

Science FDA Trials Clinical Pharmacology 40

Agency IQ

JULY 26, 2024

in equipment) for products that are more complex or aren’t as well-characterized, such as antibody drug conjugates or recombinant DNA products, will be considered higher risk than they would if the change was made to the production of standard, small molecule products. Any CMC changes (e.g.,

Biosimilars 40

Biosimilars Science FDA Production 40

Alta Sciences

APRIL 24, 2025

Altasciences was chosen by a client for an IND-enabling study of a small-molecule GLP-1 receptor agonist in canines. This presents a challenge when evaluating the test article for potential toxicological effects, since the test article is designed to produce decreased food consumption and body weight loss.

Small Molecule 52

Small Molecule Pharmacokinetics Treatment Compliance 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. All volunteers with AD had P. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

Agency IQ

JUNE 9, 2023

However, even the most innovative in vitro assays still present major limitations when it comes to fully understanding and assessing the risks of a product. However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs.

FDA 40

FDA Science Small Molecule Immune Response 40

The Pharma Data

OCTOBER 14, 2020

Results will be presented at the virtual CHEST Annual Meeting this weekend. has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. adults age 65 and older. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

FEBRUARY 25, 2022

The study met its primary goal by demonstrating pharmacokinetic equivalence in patients who switched multiple times between treatment with the two medicines. The company anticipates submitting study results for presentation at an upcoming medical congress.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

Agency IQ

DECEMBER 11, 2023

OCE leadership and staff also kept AgencyIQ staff very busy in 2023 as they attended and presented at countless meetings. In 2015, the FDA, along with the American Association for Cancer Research (AACR), held a workshop on dose optimization for small molecules. months, according to the GSK presentation.

FDA 40

FDA Science Clinical Trials Trials 40

Codon

APRIL 2, 2023

Read Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

SEPTEMBER 15, 2020

New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Drug Target Review

OCTOBER 4, 2023

Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 161 , 416–432 (2019).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

New Drug Approvals

MAY 27, 2025

PATENT PRED BY CHIRAL SEPERATION US20230065401 WO2016165014 EP4119137 chiral sepn done [0034] In one embodiment the present invention is a kit for treating a cardiac arrhythmia (e.g., Cardiovascular and Pharmacokinetic Profiles of Intravenous Etripamil in Conscious Telemetered Cynomolgus Monkeys. Ascah A, et al. Int J Toxicol.

Pharmaceuticals 67

Pharmaceuticals Small Molecule Pharmacokinetics Treatment 67